Science vs. Systems · №05
Here's the one that should be impossible. A medicine clears every hurdle — trials, regulators, approval — and still doesn't reach the children it was made for. It exists. It's legal. And it's nowhere.
We call it the Stranded Branded.
The wrong side of the last mile
The Stranded asset made it all the way to approved and then stopped — stuck on the wrong side of the last mile. No commercial engine behind it: no one to manufacture at scale, distribute, educate prescribers, or navigate access. The medicine is finished. The job isn't.
Approval is not the finish line
Approval is treated as the finish line. It isn't. Between a regulator's yes and a child's dose lies an enormous amount of unglamorous commercial work — supply, distribution, awareness, reimbursement — and for a small pediatric asset, that work often has no owner. So the medicine sits approved and inert: a success on paper that never becomes a success in practice.
Approved is not the same as available.
The answer
This is the purest version of what PediaMed Ventures does. We take approved pediatric assets that never reached scale and build the commercial last mile they're missing — manufacturing, access, adoption — so an approval finally becomes a medicine in a child's hands. Getting to approved was the science. Getting to the child is the system.
We do the second part.
Bring us the stranded
If you're holding a Stranded asset — approved, real, and somehow still not reaching kids — that gap is exactly what we close. Bring us the stranded.
The science is ready. The system isn't. That's exactly where we work.